Vivani Medical: Strategic Innovation in GLP-1 Obesity Treatment Justifies Buy Rating
Vivani Medical (VANI – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on December 20. Analyst Naz ...
FDA approves weight-loss drug Zepbound to treat sleep apnea
Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has been approved by the Food and Drug Administration for ...
pharmaphorum3h
Novo Nordisk sheds billions in value on obesity data
Novo Nordisk and Eli Lilly are currently a duopoly in the obesity market, which reached a value of $24 billion last year ...
Japan Today22h
Weight-loss drugs draw Americans back to the doctor
Powerful weight-loss drugs are expanding use of U.S. health care as patients starting prescriptions are diagnosed with ...
FDA approves weight-loss drug Zepbound for obstructive sleep apnea
The US Food and Drug Administration on Friday approved the first prescription medicine for obstructive sleep apnea: the ...
health.wusf.usf.edu20h
FDA approves weight loss drug Zepbound to treat obstructive sleep apnea
The FDA said studies have shown that by aiding weight loss, Zepbound improves sleep apnea symptoms in some patients.
The Fence Post19h
CoBank releases 2025 year ahead report — Forces that will shape the US rural economy
Meanwhile, consumers’ renewed focus on their health and the popularity of GLP-1 weight-loss drugs are showing signs of impacting food manufacturers. GLP-1 users purchase around 8% less food compared ...